Nomura Asset Management Co. Ltd. Acquires 1,885 Shares of Stryker Co. (NYSE:SYK)

Nomura Asset Management Co. Ltd. lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,892 shares of the medical technology company’s stock after buying an additional 1,885 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Stryker were worth $53,609,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new stake in shares of Stryker during the third quarter valued at about $317,000. Townsquare Capital LLC lifted its stake in Stryker by 11.9% in the 3rd quarter. Townsquare Capital LLC now owns 7,468 shares of the medical technology company’s stock worth $2,698,000 after purchasing an additional 792 shares in the last quarter. CreativeOne Wealth LLC boosted its holdings in Stryker by 46.8% in the 3rd quarter. CreativeOne Wealth LLC now owns 2,078 shares of the medical technology company’s stock valued at $751,000 after purchasing an additional 662 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Stryker by 4.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,745,971 shares of the medical technology company’s stock valued at $630,749,000 after purchasing an additional 74,224 shares in the last quarter. Finally, Financial Counselors Inc. increased its holdings in shares of Stryker by 4.3% in the third quarter. Financial Counselors Inc. now owns 38,370 shares of the medical technology company’s stock worth $13,862,000 after purchasing an additional 1,593 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

SYK stock opened at $364.38 on Friday. The stock has a market capitalization of $139.08 billion, a price-to-earnings ratio of 46.96, a PEG ratio of 2.93 and a beta of 0.95. The firm’s 50-day moving average price is $384.08 and its two-hundred day moving average price is $374.25. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm posted $3.46 EPS. As a group, equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. JPMorgan Chase & Co. raised their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Canaccord Genuity Group upped their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.